» Articles » PMID: 19010554

Effector and Suppressor Roles for LFA-1 During the Development of Experimental Autoimmune Encephalomyelitis

Overview
Journal J Neuroimmunol
Specialty Neurology
Date 2008 Nov 18
PMID 19010554
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

LFA-1 (CD11a/CD18) is a member of the beta(2)-integrin family of adhesion molecules important in leukocyte trafficking and activation. Although LFA-1 is thought to contribute to the development of experimental autoimmune encephalomyelitis (EAE) primarily through its functions on effector T cells, its importance on other leukocyte populations remains unexplored. To address this question, we performed both adoptive transfer EAE experiments involving CD11a(-/-) mice and trafficking studies using bioluminescent T cells expressing luciferase under the control of a CD2 promoter (T-lux cells). Transfer of encephalitogenic CD11a(-/-) T cells to wild type mice resulted in a significant reduction in overall EAE severity compared to control transfers. We also observed, using in vivo imaging techniques, that CD11a(-/-) T-lux cells readily infiltrated lymph nodes and the CNS of wild type recipients with kinetics comparable to CD11a(+/+) transfers, although their overall numbers in these organs were reduced. Surprisingly, transfer of encephalitogenic wild type T cells to CD11a(-/-) mice induced a severe and sometimes fatal EAE disease course, associated with massive T cell infiltration and proliferation in the CNS. These data indicate that LFA-1 expression on leukocytes in recipient mice plays an important immunomodulatory role in EAE. Thus, LFA-1 acts as a key regulatory adhesion molecule during the development of EAE, serving both pro- and anti-inflammatory roles in disease pathogenesis.

Citing Articles

Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis.

Rad L, Hughes K, Wheeler S, Decker J, Orbach S, Galvan A Proc Natl Acad Sci U S A. 2025; 122(7):e2409852122.

PMID: 39937858 PMC: 11848328. DOI: 10.1073/pnas.2409852122.


LFA-1 knockout inhibited the tumor growth and is correlated with treg cells.

Niu T, Li Z, Huang Y, Ye Y, Liu Y, Ye Z Cell Commun Signal. 2023; 21(1):233.

PMID: 37723552 PMC: 10506322. DOI: 10.1186/s12964-023-01238-6.


Exercise training alters autoimmune cell invasion into the brain in autoimmune encephalomyelitis.

Hamdi L, Nabat H, Goldberg Y, Fainstein N, Segal S, Mediouni E Ann Clin Transl Neurol. 2022; 9(11):1792-1806.

PMID: 36217574 PMC: 9639625. DOI: 10.1002/acn3.51677.


A CRISPR screen targeting PI3K effectors identifies RASA3 as a negative regulator of LFA-1-mediated adhesion in T cells.

Johansen K, Golec D, Huang B, Park C, Thomsen J, Preite S Sci Signal. 2022; 15(743):eabl9169.

PMID: 35857633 PMC: 9637254. DOI: 10.1126/scisignal.abl9169.


Calcineurin inhibitors suppress acute graft-versus-host disease via NFAT-independent inhibition of T cell receptor signaling.

Otsuka S, Melis N, Gaida M, Dutta D, Weigert R, Ashwell J J Clin Invest. 2021; 131(11).

PMID: 33822776 PMC: 8159692. DOI: 10.1172/JCI147683.


References
1.
Laschinger M, Vajkoczy P, Engelhardt B . Encephalitogenic T cells use LFA-1 for transendothelial migration but not during capture and initial adhesion strengthening in healthy spinal cord microvessels in vivo. Eur J Immunol. 2003; 32(12):3598-606. DOI: 10.1002/1521-4141(200212)32:12<3598::AID-IMMU3598>3.0.CO;2-6. View

2.
Kuchroo V, Anderson A, Waldner H, Munder M, Bettelli E, Nicholson L . T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol. 2002; 20:101-23. DOI: 10.1146/annurev.immunol.20.081701.141316. View

3.
Azadniv M, Dugger K, Bowers W, Weaver C, Crispe I . Imaging CD8+ T cell dynamics in vivo using a transgenic luciferase reporter. Int Immunol. 2007; 19(10):1165-73. DOI: 10.1093/intimm/dxm086. View

4.
Bullard D, Hu X, Schoeb T, Axtell R, Raman C, Barnum S . Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis. J Immunol. 2005; 175(10):6327-33. DOI: 10.4049/jimmunol.175.10.6327. View

5.
Gordon E, Myers K, Dougherty J, Rosen H, Ron Y . Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol. 1995; 62(2):153-60. DOI: 10.1016/0165-5728(95)00120-2. View